Drug intelligence / Profile preview

TPX-124

Development stage: Preclinical
Lead developer: Tego Science
Modality: Cell Therapies
Administration: Topical

Overview

TPX-124 is a preclinical-stage cell therapy candidate being developed by Tego Science for the treatment of hair loss (alopecia). The therapy utilizes a hair growth-promoting protein to stimulate hair follicles and encourage regrowth. As a regenerative medicine approach, it aims to address the underlying causes of hair loss through cellular intervention. The program is currently in the preclinical phase of development within Tego Science's R&D pipeline.

Beyond the preview

Go deeper on TPX-124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPX-124.

Explore the full profile